---
document_datetime: 2023-09-21 18:27:52
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ipreziv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: ipreziv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9118406
conversion_datetime: 2025-12-25 08:07:55.375372
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ipreziv

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| A31/0006             | On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit-risk of dual RAS blockade therapy through the combined Medicinal | 22/05/2014 product                  | 09/09/2014                                     | SmPC and PL                      | For further information please refer to the Renin-angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report. |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.                                                                                                                                                                           |                    |                                                                                                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------------------------------------|
| T/0012    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                           | 07/04/2014         | SmPC, Labelling and PL Transfer of the Marketing Authorisation to Takeda Pharma A/S. authorised |
| PSUV/0010 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/03/2014         | PRAC Recommendation - maintenance                                                               |
| IG/0408/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                 | 24/02/2014 no      | SmPC, Labelling and PL longer                                                                   |
| WS/0464/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. - To add a new supplier of an starting material. - To add a new supplier of an starting material. - Change in the manufacturing process of the active substance. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other Medicinal | 18/12/2013 product |                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |                      | authorised            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0008 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/09/2013 | 11/11/2013           | SmPC                  | For further information please refer to: Ipreziv-H-2517-Grounds-PSUV-08-en.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| WS/0405   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.3, 4.4, 4.5, and 4.8 of the SmPC, as per the PRAC/CHMP request set out in the PRAC PSUR Assessment Report dated 7 March 2013, in order to: - include relevant contraindications and warnings regarding concomitant use of azilsartan medoxomil and aliskiren (section 4.3, 4.4 and 4.5); - include the adverse drug reactions 'rash', 'pruritus', 'nausea' and 'muscle spasm' with the frequency 'uncommon' (section 4.8). The Package Leaflet is updated accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data Medicinal product | 19/09/2013 | 11/11/2013 no longer | SmPC, Annex II and PL | The MAH was requested in the conclusions of the final PRAC PSUR assessment report (AR) covering the period 25 February 2012 to 24 August 2012 (EMEA/H/C/002293/PSU 003 and EMEA/H/C/002517/PSU 003) to submit a Type II variation in order to include relevant contraindications and warnings regarding concomitant use of azilsartan medoxomil and aliskiren. A few published studies building upon the preliminary results of the ALTITUDE study which raised safety concerns regarding dual renin-angiotensin system (RAAS) blockade when aliskiren was co-administered with angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) in patients with Type II diabetes mellitus and renal impairment, was the evidence that supported the PRAC request. To be noted that azilsartan medoxomil is an angiotensin II receptor blocker (ARB), indicated for the treatment of essential hypertension in adults. The preliminary results of ALTITUDE study were assessed by the CHMP as part of an Article 20 of Regulation (EC) No 726/2004Article referral procedure (EMEA/H/C/000780/A-20/0063) initiated by the EC covering all aliskiren containing products. The CHMP opinion was issued in February 2012. At that time, based on the available |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |               |                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|---------------------------------|
| IG/0285   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/04/2013 | n/a           |                                 |
| IG/0231   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/11/2012 | n/a           |                                 |
| IG/0164/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.4.a - Change in shape or dimensions of the packaging) - Medicinal product | 20/04/2012 | n/a no longer | container or closure (immediate |

<div style=\"page-break-after: always\"></div>

| IB/0001/G   | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished   | 20/04/2012   | n/a   | SmPC, Labelling and PL   |
|-------------|---------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------|

<!-- image -->